Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Endocrinology, Diabetes and Metabolism
Reference118 articles.
1. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer;Herbst;J Clin Oncol,2010
2. A first-in-human study of conatumumab in adult patients with advanced solid tumors;Herbst;Clin Cancer Res,2010
3. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer;Kindler;Ann Oncol,2012
4. A randomized, phase 2 study of paclitaxel (P) and carboplatin (C)±conatumumab (CON) for first-line treatment of non-small cell lung cancer (NSCLC);Paz Ares;ESMO Congress,2010
5. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer;Soria;J Clin Oncol,2010
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献